|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
We showed that ectopic expression of this gene, designated as breast cancer antiestrogen resistance 4 (BCAR4), caused OH-TAM resistance and anchorage-independent cell growth in ZR-75-1 cells and that the intact open reading frame was required for its function.
|
16778085 |
2006 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We showed that ectopic expression of this gene, designated as breast cancer antiestrogen resistance 4 (BCAR4), caused OH-TAM resistance and anchorage-independent cell growth in ZR-75-1 cells and that the intact open reading frame was required for its function.
|
16778085 |
2006 |
|
Mammary Neoplasms
|
0.330 |
AlteredExpression
|
group |
LHGDN |
Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells.
|
16778085 |
2006 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.
|
20859285 |
2010 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
CTD_human |
Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.
|
20859285 |
2010 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.
|
20859285 |
2010 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.
|
20859285 |
2010 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
BCAR4 mRNA levels were measured in primary breast tumours, and evaluated for association with progression-free survival (PFS) and clinical benefit in patients with oestrogen receptor (ERα)-positive tumours receiving tamoxifen as first-line monotherapy for advanced disease.
|
20859285 |
2010 |
|
Mammary Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
BCAR4 mRNA levels were measured in primary breast tumours, and evaluated for association with progression-free survival (PFS) and clinical benefit in patients with oestrogen receptor (ERα)-positive tumours receiving tamoxifen as first-line monotherapy for advanced disease.
|
20859285 |
2010 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.
|
20859285 |
2010 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.
|
20859285 |
2010 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In a separate cohort of patients with lymph node-negative, ERα-positive cancer, and not receiving systemic adjuvant therapy, BCAR4 levels were evaluated for association with distant metastasis-free survival (MFS).
|
20859285 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High BCAR4 mRNA levels were associated with poor MFS and overall survival, reflecting tumour aggressiveness.
|
20859285 |
2010 |
|
Thymoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In BCAR4-expressing cells, phosphorylation of v-erb-b2 erythroblastic leukaemia viral oncogene homolog (ERBB)2, ERBB3, and their downstream mediators extracellular signal-regulated kinase 1/2 and v-akt murine thymoma viral oncogene homolog (AKT) 1/2, was increased.
|
20859285 |
2010 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer antiestrogen resistance 4 (BCAR4) was identified in a functional screen for genes involved in tamoxifen resistance.
|
21506106 |
2011 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
CTD_human |
Forced expression of BCAR4 in human ZR-75-1 and MCF7 breast cancer cells resulted in cell proliferation in the absence of estrogen and in the presence of various antiestrogens.
|
21506106 |
2011 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Forced expression of BCAR4 in human ZR-75-1 and MCF7 breast cancer cells resulted in cell proliferation in the absence of estrogen and in the presence of various antiestrogens.
|
21506106 |
2011 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer antiestrogen resistance 4 (BCAR4) was identified in a functional screen for genes involved in tamoxifen resistance.
|
21506106 |
2011 |
|
Mammary Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
BCAR4 is expressed in 27% of primary breast tumors.
|
21506106 |
2011 |
|
Mammary Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
BCAR4 is expressed in 27% of primary breast tumors.
|
21506106 |
2011 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
|
21506106 |
2011 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
|
21506106 |
2011 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Regarding tumor aggressiveness high BCAR4 mRNA levels are associated with a shorter metastasis free survival and overall survival.
|
21506106 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Regarding tumor aggressiveness high BCAR4 mRNA levels are associated with a shorter metastasis free survival and overall survival.
|
21506106 |
2011 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reverse transcriptase-PCR analysis showed that 27.6% of the breast cancers were positive for BCAR4 and 22% expressed also low levels of ERBB2.
|
22892392 |
2012 |